X-Message-Number: 13394 Date: Wed, 15 Mar 2000 15:02:40 -0800 From: Olaf Henny <> Subject: ALT-711; New Study References: <> The new study report released below is a further indication that the benefits of ALT-711 may have some rejuvenating effects on all parts of the human anatomy, once clinical trials have proved the efficacy of the compound for humans. I find that exciting and hope that they get on with it soon. Best, Olaf For full article see: http://www.corporate-ir.net/ireye/ir_site.zhtml?ticker=altn&script=400 RAMSEY, N.J., March 15 /PRNewswire/ -- Alteon Inc. (OTC Bulletin Board: ALTN), announced today that a new pre-clinical study of ALT-711, lead Advanced Glycosylation End-Product ("A.G.E.") Crosslink Breaker, has been published in the March 14th issue of the Proceedings of the National Academy of Sciences (PNAS). The article details ALT-711's ability to reverse cardiac stiffness in aged dogs, restoring the cardiovascular system to a state found in younger animals. In this study, administration of ALT-711 daily for one month resulted in a 40% reduction in age-related ventricular stiffness, or hardening. This decrease in stiffness was accompanied by an overall improvement in cardiac function, as evidenced by increased left ventricular end-diastolic volume, stroke volume and decreased end-diastolic pressure. Rate This Message: http://www.cryonet.org/cgi-bin/rate.cgi?msg=13394